Table 4 Patient information for predominant histological subtypes in pathological stage II + IIIA
Total | Group B (Lepidic) | Group C (Papillary + acinar + variant) | Group D (Solid + micropapillary) | p-value | ||
|---|---|---|---|---|---|---|
n | 697 | 57 | 503 | 137 | ||
Sex (male/female), n (%) | 426/271 (61.1%) | 34/23 (58.8%) | 305/198 (60.8%) | 87/50 (63.5%) | 0.905 | |
Age, mean ± SD | 66.57 ± 9.53 | 68.00 ± 8.35 | 66.71 ± 9.69 | 65.41 ± 9.45 | 0.223 | |
Smoking history ( ±), n (%) | 424/248 (63.2%) | 34/23 (58.8%) | 291/194 (60.6%) | 99/31 (76.2%) | 0.003 | |
Operation time (min.), mean ± SD | 217.89 ± 72.68 | 219.02 ± 76.10 | 219.27 ± 72.75 | 213.19 ± 71.95 | 0.711 | |
Invasion, n (%) | ||||||
Lymphatic vessel invasion ( ±) | 406/219 (65.0%) | 24 /29 (45.2%) | 293/155 (65.4%) | 89/35 (71.8%) | < 0.001 | |
Vascular invasion ( ±) | 345/282 (55.1%) | 13/40 (26.5%) | 246/206 (54.4%) | 86/38 (70.5%) | < 0.001 | |
Pleural invasion ( ±) | 324/396 (45.0%) | 12/45 (23.5%) | 226/275 (45.1%) | 70/65 (51.9%) | < 0.001 | |
EGFR mutation ( ±) | 182/284 (39.5%) | 16/22 (44.1%) | 142/197 (41.9%) | 24/65 (27.0%) | 0.048 | |
Adjuvant therapy ( ±) | 453/233 (66.0%) | 36/19 (63.3%) | 319/177 (64.3%) | 98/37 (72.6%) | 0.249 | |
Pathological stage II / IIIA | 375/322 (53.8%) | 25/32 (43.9%) | 270/233 (53.7%) | 73/64 (53.3%) | 0.960 | |